DOVER, Del., Oct. 13, 2025 -- Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors targeting escape mutations in hematologic malignancies and solid tumors, today announced the presentation of data for its brain- and lung-permeable pan-EGFR inhibitor, ZE77-0273 is a reversible small-molecule drug candidate that demonstrates broad activity against resistance mutations in EGFR-mutant non-small cell lung cancer (NSCLC), a high selectivity index versus wild-type EGFR, and a wide therapeutic window characterized by excellent safety and tolerability.
About Eilean Therapeutics
Eilean Therapeutics is a biopharmaceutical company focused on the development of best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies and solid tumors. Utilizing its proprietary hybrid AI/ML drug design platform, the company leverages proprietary partner data, advanced chem/bio tools, and deep domain expertise to identify highly valuable molecular targets, accelerate drug discovery, and optimize the development of highly differentiated therapies.
Eilean's oncology programs for therapy-resistant lung cancer include best-in-class reversible pan-EGFR inhibitor, c-Met inhibitor, and pan-KRAS molecular glue.
For more information, visit www.eileanther.com
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
